Skip to content
Clinical Trials – home

Azienda Ospedaliero-Universitaria San Luigi Gonzaga

Research site

Italy Regione Gonzole 10, 10043 Orbassano, Italy

  • 84 trials recruiting
  • Non-small cell lung cancer · Non-small cell lung cancer metastatic · Non-small cell lung cancer stage IV
  • Adults and children

About Specializations

Azienda Ospedaliero-Universitaria San Luigi Gonzaga in Orbassano, Italy specialises in clinical trials of conditions such as Non-small cell lung cancer, Non-small cell lung cancer metastatic, Non-small cell lung cancer stage IV, Bladder cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Hematology

At Azienda Ospedaliero-Universitaria San Luigi Gonzaga, much of the clinical research focuses on neoplasms and blood disorders, with studies spanning non-small cell lung cancer, small cell lung cancer, prostate cancer, renal cell carcinoma, colorectal cancer, head and neck cancer, mesothelioma, gastrointestinal stromal tumor, lymphoma, and myelodysplastic syndrome. These trials are designed to test new treatment approaches, compare them with current standards, and improve outcomes for people with advanced or hard-to-treat cancers.

  • Evaluating new cancer therapies for advanced lung cancer and other solid tumors
  • Comparing treatment effectiveness in prostate cancer and renal cell carcinoma
  • Studying better options for lymphoma and myelodysplastic syndrome

The site’s oncology program reflects a strong interest in both extending survival and refining care for patients with complex malignancies.

Respiratory and Rare Disease Research

Clinical trials here also address respiratory tract diseases and selected rare conditions, including cystic fibrosis and systemic sclerosis-associated interstitial lung disease. Researchers are exploring ways to improve lung function, reduce disease burden, and identify more effective treatment options for patients with chronic and uncommon pulmonary disorders.

  • Testing therapies aimed at improving outcomes in cystic fibrosis
  • Assessing treatment benefits for systemic sclerosis-associated interstitial lung disease
  • Supporting research into better management of chronic lung disease

This mix of studies shows a commitment to both common respiratory illness and rare, high-need disease areas.

Hematologic and Genetic Blood Disorders

The site is active in research on inherited and acquired blood conditions, including alpha-thalassemia, beta-thalassemia, and anemia linked to myelodysplastic syndrome. These trials aim to improve red blood cell production, reduce transfusion needs, and support safer, more effective care for patients with chronic hematologic disease.

  • Exploring new options for thalassemia in adults, adolescents, and children
  • Evaluating treatments for anemia in myelodysplastic syndrome
  • Advancing care for transfusion-dependent blood disorders

These studies highlight a strong focus on inherited hemoglobin disorders and supportive care for patients living with long-term blood diseases.

Cardiovascular and Critical Care

Research at the Department of SCDU Oncologia Medica, AOU San Luigi Orbassano extends beyond cancer into urgent care settings, including acute myocardial infarction and critical illness. The trials are aimed at improving early intervention, preventing serious complications, and strengthening emergency treatment strategies for high-risk patients.

  • Studying ways to reduce complications in acute myocardial infarction
  • Testing approaches to prevent collapse during tracheal intubation
  • Improving emergency response in critically ill adults

These investigations support better decision-making in time-sensitive cardiovascular and intensive care situations.

Metabolic and Autoimmune Conditions

The site also includes studies in type 2 diabetes mellitus and skin and connective tissue diseases, reflecting interest in chronic conditions that require long-term management. In parallel, trials in systemic sclerosis are examining whether treatment can slow lung decline and improve overall disease control.

  • Evaluating participant-centered trial approaches in type 2 diabetes mellitus
  • Testing therapies for systemic sclerosis with lung involvement
  • Exploring better long-term management of chronic metabolic and autoimmune disease

These studies aim to make treatment more effective and more practical for people managing ongoing complex illnesses.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Regione Gonzole 1010043 OrbassanoItaly
Recruiting now
84 trials
Conditions studied
104

More sites in OrbassanoItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

215 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S
Countries:ItalyItaly
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Exelixis Inc.

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Neoplasm

Recruiting

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.